Drug Profile
Research programme: diabetes/obesity therapies - AstraZeneca
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Columbia University
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 17 Jun 2008 AstraZeneca enters research collaboration with Columbia University Medical Center to develop therapies primarily for type 2 diabetes mellitus and obesity, with secondary focus on therapies for atherosclerosis/dyslipidaemia